Involvement of the p53 tumor-suppressor protein in the development of antinociceptive tolerance to morphine. 2009

Koichi Tan-No, and Masakazu Shimoda, and Kenya Watanabe, and Osamu Nakagawasai, and Fukie Niijima, and Syu-Ichi Kanno, and Masaaki Ishikawa, and Georgy Bakalkin, and Takeshi Tadano
Department of Pharmacology, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan. koichi@tohoku-pharm.ac.jp

The present study was designed to determine whether the p53 tumor-suppressor protein is involved in the development of antinociceptive tolerance to morphine. When the doses of morphine (mg/kg per injection) were subcutaneously given into mice as pretreatment twice daily for 2 days (first day (30) and second day (60)), intrathecal (i.t.) administration of morphine (0.1nmol) was inactive due to antinociceptive tolerance in the 0.5% formalin test on the third day. Tolerance to i.t. morphine was significantly suppressed by i.t. injection of pifithrin-alpha (1 and 10nmol), an inhibitor of p53 activation, benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone (Z-VAD-fmk) (1 and 10nmol), a non-selective caspase inhibitor, or N(G)-nitro-l-arginine methyl ester (l-NAME) (2 and 20nmol), a non-selective inhibitor of nitric oxide synthase, 5min before each morphine treatment during the induction, with none given on the test day. Moreover, p53 expression in the spinal cord had increased significantly 14h after the last morphine administration. These results indicate that the increased expression and activation of p53, and the nitric oxide and caspase systems related to p53 may contribute to the development of antinociceptive tolerance to morphine in the mouse spinal cord.

UI MeSH Term Description Entries
D007278 Injections, Spinal Introduction of therapeutic agents into the spinal region using a needle and syringe. Injections, Intraspinal,Injections, Intrathecal,Intraspinal Injections,Intrathecal Injections,Spinal Injections,Injection, Intraspinal,Injection, Intrathecal,Injection, Spinal,Intraspinal Injection,Intrathecal Injection,Spinal Injection
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D008297 Male Males
D009020 Morphine The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle. Morphine Sulfate,Duramorph,MS Contin,Morphia,Morphine Chloride,Morphine Sulfate (2:1), Anhydrous,Morphine Sulfate (2:1), Pentahydrate,Oramorph SR,SDZ 202-250,SDZ202-250,Chloride, Morphine,Contin, MS,SDZ 202 250,SDZ 202250,SDZ202 250,SDZ202250,Sulfate, Morphine
D009294 Narcotics Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. Analgesics, Narcotic,Narcotic Analgesics,Narcotic,Narcotic Effect,Narcotic Effects,Effect, Narcotic,Effects, Narcotic
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D010146 Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS. Suffering, Physical,Ache,Pain, Burning,Pain, Crushing,Pain, Migratory,Pain, Radiating,Pain, Splitting,Aches,Burning Pain,Burning Pains,Crushing Pain,Crushing Pains,Migratory Pain,Migratory Pains,Pains, Burning,Pains, Crushing,Pains, Migratory,Pains, Radiating,Pains, Splitting,Physical Suffering,Physical Sufferings,Radiating Pain,Radiating Pains,Splitting Pain,Splitting Pains,Sufferings, Physical
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug

Related Publications

Koichi Tan-No, and Masakazu Shimoda, and Kenya Watanabe, and Osamu Nakagawasai, and Fukie Niijima, and Syu-Ichi Kanno, and Masaaki Ishikawa, and Georgy Bakalkin, and Takeshi Tadano
November 2010, Neuroscience letters,
Koichi Tan-No, and Masakazu Shimoda, and Kenya Watanabe, and Osamu Nakagawasai, and Fukie Niijima, and Syu-Ichi Kanno, and Masaaki Ishikawa, and Georgy Bakalkin, and Takeshi Tadano
May 1973, Experientia,
Koichi Tan-No, and Masakazu Shimoda, and Kenya Watanabe, and Osamu Nakagawasai, and Fukie Niijima, and Syu-Ichi Kanno, and Masaaki Ishikawa, and Georgy Bakalkin, and Takeshi Tadano
December 2010, Peptides,
Koichi Tan-No, and Masakazu Shimoda, and Kenya Watanabe, and Osamu Nakagawasai, and Fukie Niijima, and Syu-Ichi Kanno, and Masaaki Ishikawa, and Georgy Bakalkin, and Takeshi Tadano
December 2012, The American journal of the medical sciences,
Koichi Tan-No, and Masakazu Shimoda, and Kenya Watanabe, and Osamu Nakagawasai, and Fukie Niijima, and Syu-Ichi Kanno, and Masaaki Ishikawa, and Georgy Bakalkin, and Takeshi Tadano
January 1985, Neurobehavioral toxicology and teratology,
Koichi Tan-No, and Masakazu Shimoda, and Kenya Watanabe, and Osamu Nakagawasai, and Fukie Niijima, and Syu-Ichi Kanno, and Masaaki Ishikawa, and Georgy Bakalkin, and Takeshi Tadano
October 2022, Biomolecules,
Koichi Tan-No, and Masakazu Shimoda, and Kenya Watanabe, and Osamu Nakagawasai, and Fukie Niijima, and Syu-Ichi Kanno, and Masaaki Ishikawa, and Georgy Bakalkin, and Takeshi Tadano
April 1997, FEBS letters,
Koichi Tan-No, and Masakazu Shimoda, and Kenya Watanabe, and Osamu Nakagawasai, and Fukie Niijima, and Syu-Ichi Kanno, and Masaaki Ishikawa, and Georgy Bakalkin, and Takeshi Tadano
January 2015, British journal of pharmacology,
Koichi Tan-No, and Masakazu Shimoda, and Kenya Watanabe, and Osamu Nakagawasai, and Fukie Niijima, and Syu-Ichi Kanno, and Masaaki Ishikawa, and Georgy Bakalkin, and Takeshi Tadano
September 2001, Molecular cell,
Koichi Tan-No, and Masakazu Shimoda, and Kenya Watanabe, and Osamu Nakagawasai, and Fukie Niijima, and Syu-Ichi Kanno, and Masaaki Ishikawa, and Georgy Bakalkin, and Takeshi Tadano
December 1999, The Journal of biological chemistry,
Copied contents to your clipboard!